Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Allogene Therapeutics stock in Canada

Own Allogene Therapeutics shares in just a few minutes.

Allogene Therapeutics is a biotechnology business based in the US. Allogene Therapeutics stocks (ALLO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $24.18 – a decrease of 4.46% over the previous week. Allogene Therapeutics employs 301 staff and has a trailing 12-month revenue of around $38.4 million.

How to buy shares in Allogene Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ALLO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Allogene Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Allogene Therapeutics's stock price?

Since the stock market crash in March caused by coronavirus, Allogene Therapeutics's stock price has had significant negative movement.

Its last market close was $11.78, which is 54.71% down on its pre-crash value of $26.01 and 47.96% down on the lowest point reached during the March crash when the stocks fell as low as $17.43.

If you had bought $1,000 worth of Allogene Therapeutics stocks at the start of February 2020, those stocks would have been worth $869.71 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $538.94.

Allogene Therapeutics stock price (NASDAQ:ALLO)

Use our graph to track the performance of ALLO stocks over time.

Allogene Therapeutics shares at a glance

Information last updated 2022-01-17.
Latest market close$11.78
52-week range$11.54 - $39.12
50-day moving average $16.64
200-day moving average $22.72
Wall St. target price$32.38
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.88

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Allogene Therapeutics price performance over time

Historical closes compared with the close of $11.78 from 2022-01-18

1 week (2022-01-11) -8.68%
1 month (2021-12-17) -25.49%
3 months (2021-10-18) -25.11%
6 months (2021-07-19) -47.13%
1 year (2021-01-19) -62.72%
2 years (2020-01-17) -53.48%
3 years (2019-01-18) 28.58
5 years (2017-01-15) N/A

Allogene Therapeutics financials

Revenue TTM $38.4 million
Gross profit TTM $0
Return on assets TTM -13.65%
Return on equity TTM -24.01%
Profit margin 0%
Book value $6.81
Market capitalisation $1.9 billion

TTM: trailing 12 months

Allogene Therapeutics share dividends

We're not expecting Allogene Therapeutics to pay a dividend over the next 12 months.

Allogene Therapeutics share price volatility

Over the last 12 months, Allogene Therapeutics's shares have ranged in value from as little as $11.54 up to $39.12. A popular way to gauge a stock's volatility is its "beta".

ALLO.US volatility(beta: 0.7)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Allogene Therapeutics's is 0.7013. This would suggest that Allogene Therapeutics's shares are less volatile than average (for this exchange).

Allogene Therapeutics overview

Allogene Therapeutics, Inc. , a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc. ; Servier; Cellectis S.

Stocks similar to Allogene Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site